Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
2024 ASCO Annual Meeting
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Charter two was found positive for the primary outcome. At the time of the report of the results, there was a statistically significant difference of five months in terms of progression-free survival in favor of the patients who received cabazitaxel plus abirateron. For patients who received cabazitaxel and abirateron, the median progression-free survival was 14.9 months versus 9.9 months for the patients who received abirateron alone. So technically, the addition of cabazitaxel prolonged the progression-free survival by a little bit more than 50%.
Even though charter two was found positive for the primary outcome, it is not a practice changing study. The main reason is because the landscape, the treatment landscape for metastatic castration-sensitive disease has changed, and there are not that many patients who are currently getting docetaxel plus androgen deprivation in the castration-sensitive setting.
Nowadays, most patients receive either a double treatment, which includes treatment with abirateron or enzalutamide or any of the other second generation androgen receptor inhibitors. In cases that the patients receive treatment with docetaxel, that is usually in the context of a triplet therapy, which means that in addition to the docetaxel, they also receive treatment with abirateron or darolutamide or enzalutamide. That is the main reason that by the time these patients develop castration-resistant disease, they have already been exposed to a second generation androgen receptor inhibitor, which of course is like abirateron.
As part of charter two, we did include two correlative studies that are in progress. The first one is the analysis of circulating tumor cells for splice variant seven, and the second one that we included in charter two was disease assessment using sodium fluoride PET imaging. This is ongoing work and hopefully we will be able to present those results in the future meeting. Also, as part of the study, we did collect plasma for patients who enrolled in the study, and we hope that we will be able to secure funding for some additional studies with those samples.
The ASCO Post Staff
Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; and DB07 on trastuzumab deruxtecan with or without palbociclib.
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).
The ASCO Post Staff
Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.
The ASCO Post Staff
Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).